118 filings
Page 3 of 6
8-K
4ez43zhl2kyx0vtec8i
15 Mar 23
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
7:45am
8-K
gl3yrfzmvm5e9q
10 Mar 23
Regulation FD Disclosure
4:35pm
424B5
z1lmxym dse4
10 Mar 23
Prospectus supplement for primary offering
7:53am
8-K
jhzjaj
10 Mar 23
Entry into a Material Definitive Agreement
7:51am
8-K
xfap6rmqfs4xx5padv7
22 Feb 23
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
8:14am
8-K
sqvfksc5kjw3qlssn60o
13 Feb 23
Other Events
8:00am
EFFECT
hfm2 dcm904inla
4 Jan 23
Notice of effectiveness
12:15am
CORRESP
j0x16d y5
29 Dec 22
Correspondence with SEC
12:00am
UPLOAD
4vsdr 7ksg6ny2z2r8y
28 Dec 22
Letter from SEC
12:00am
8-K
7s1grwsocvwur1afafq4
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
5c0sys
23 Dec 22
Shelf registration
4:16pm
8-K
giexnrp
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
jm7w u0cumcx5dl
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
t62yzl6n
14 Nov 22
Prospectus supplement with pricing info
6:02am
EFFECT
7be9v1bmrb1 jl
10 Nov 22
Notice of effectiveness
12:15am
CORRESP
ctw988ei6w ke7
7 Nov 22
Correspondence with SEC
12:00am
CORRESP
bpo13v
7 Nov 22
Correspondence with SEC
12:00am
UPLOAD
ntj2tgqf42q6
24 Oct 22
Letter from SEC
12:00am